


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1. (Original) The use of N-(4,5,6,7-tetrahydro-thiazolo-[5,4-c]pyridin-2-yl)-(C<sub>6-18</sub>)arylsulfonamides, wherein the nitrogen atom of the pyridine is substituted, and wherein the pyridine ring is optionally bridged, in the preparation of a medicament for the treatment of a disorder mediated by the action of steroid sulfatase.

Claim 2. (Original) The use of claim 1, wherein an N-(4,5,6,7-tetrahydro-thiazolo-[5,4-c]pyridin-2-yl)-(C<sub>6-18</sub>)arylsulfonamide is a compound of formula



wherein

R<sub>1</sub> is unsubstituted (C<sub>6-18</sub>)aryl, or (C<sub>6-18</sub>)aryl substituted by aminocarbonyl, halogen or halo(C<sub>1-6</sub>)alkyl,

R<sub>2</sub> is (C<sub>1-12</sub>)alkoxycarbonyl, (C<sub>1-6</sub>)alkylcarbonyl, (C<sub>3-6</sub>)cycloalkyl(C<sub>1-6</sub>)alkylcarbonyl or unsubstituted (C<sub>6-18</sub>)aryl, or (C<sub>6-18</sub>)aryl substituted by aminocarbonyl, halogen or halo(C<sub>1-6</sub>)alkyl, and


EITHER

- R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are hydrogen

OR

- R<sub>3</sub> and R<sub>5</sub> together are (C<sub>1-4</sub>)alkylene and R<sub>4</sub> is hydrogen.

Claim 3. (Original) A compound of formula




wherein

R<sub>1</sub> is unsubstituted (C<sub>6-18</sub>)aryl, or (C<sub>6-18</sub>)aryl substituted by aminocarbonyl, halogen or halo(C<sub>1-6</sub>)alkyl,

R<sub>2</sub>' is (C<sub>1-12</sub>)alkoxycarbonyl, (C<sub>1-6</sub>)alkylcarbonyl, (C<sub>3-6</sub>)cycloalkyl(C<sub>1-6</sub>)alkylcarbonyl or unsubstituted (C<sub>6-18</sub>)aryl, or (C<sub>6-18</sub>)aryl substituted by aminocarbonyl, halogen or halo(C<sub>1-6</sub>)alkyl, R<sub>3</sub> and R<sub>5</sub> together are (C<sub>1-4</sub>)alkylene, and R<sub>4</sub> is hydrogen.

Claim 4. (Original) A compound of formula



wherein

R<sub>1</sub> is unsubstituted (C<sub>6-18</sub>)aryl, or (C<sub>6-18</sub>)aryl substituted by aminocarbonyl, halogen or halo(C<sub>1-6</sub>)alkyl, and


R<sub>2</sub>'' is (C<sub>1-12</sub>)alkoxycarbonyl, (C<sub>3-6</sub>)cycloalkyl(C<sub>1-6</sub>)alkylcarbonyl, unsubstituted (C<sub>6-18</sub>)aryl, or (C<sub>6-18</sub>)aryl substituted by aminocarbonyl, halogen or halo(C<sub>1-6</sub>)alkyl.

Claim 5. (Original) A compound of formula II, which is

N-(3-thia-5,11-diaza-tricyclo[6.2.1.0\*2,6\*]undeca-2(6),4-dien-4-yl)-benzenesulfonamide, or a compound of formula III, which is selected from the group consisting of

- 2-[2-(3,5-Bis-trifluoromethyl-benzenesulfonylamino)-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-5-yl]-4-trifluoromethyl-benzamide,
- 2-[2-(2,3-Dichloro-benzenesulfonylamino)-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-5-yl]-4-trifluoromethyl-benzamide,
- 2-[2-(3,5-Dichloro-benzenesulfonylamino)-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-5-yl]-4-trifluoromethyl-benzamide,
- 2-(3,5-Bis-trifluoromethyl-benzenesulfonamino)-6,7-dihydro-4H-thiazolo[5,4-c]pyridine-5-carboxylic acid tert-butyl ester,
- 2-(2,3-Dichloro-benzenesulfonamino)-6,7-dihydro-4H-thiazolo[5,4-c]pyridine-5-carboxylic acid tert-butyl ester,
- 2-(3,5-Dichloro-benzenesulfonamino)-6,7-dihydro-4H-thiazolo[5,4-c]pyridine-5-carboxylic acid tert-butyl ester, and
- N-[5-(2-Cyclopentyl-acetyl)-4,5,6,7-tetrahydro-thiazolo[5,4-c]pyridin-2-yl]-3,5-bis-trifluoromethyl-benzenesulfonamide.

Claim 6. (Currently amended) A compound according to ~~any one of~~ claims 4 ~~or~~ 5 of formula




Claim 7. (Currently amended) A compound of ~~any one of~~ according to claims 3 ~~to 6~~ in the form of a salt.

Claim 8. (Currently amended) A compound of ~~any one of~~ according to claims 3 ~~to 7~~ for use as a pharmaceutical.

Claim 9. (Currently amended) A pharmaceutical composition comprising a pharmaceutically effective amount of at least one compound of ~~any one of~~ according to claims 3 ~~to 7~~ in association with at least one pharmaceutically acceptable excipient.


Claim 10. (Original) A method of treating disorders mediated by the action of steroid sulfatase comprising administering a therapeutically effective amount of an N-(4,5,6,7-tetrahydro-thiazolo-[5,4-c]pyridin-2-yl)-(C<sub>6-18</sub>)arylsulfonamide, wherein the nitrogen atom of the pyridine is substituted, and wherein the pyridine ring is optionally bridged, to a subject in need of such treatment.

Claim 11. (Currently amended) A compound of formula




wherein X has the meaning of R<sub>2</sub>' ~~in claim 4 is~~ (C<sub>1-12</sub>)alkoxycarbonyl, (C<sub>3-6</sub>)cycloalkyl(C<sub>1-6</sub>)alkylcarbonyl, unsubstituted (C<sub>6-18</sub>)aryl, or (C<sub>6-18</sub>)aryl substituted by aminocarbonyl, halogen or halo(C<sub>1-6</sub>)alkyl, or

a compound of formula



wherein X ~~has the meaning of R<sub>2</sub>' as defined in claim 3 is~~ (C<sub>1-12</sub>)alkoxycarbonyl, (C<sub>1-6</sub>)alkylcarbonyl, (C<sub>3-6</sub>)cycloalkyl(C<sub>1-6</sub>)alkylcarbonyl or unsubstituted (C<sub>6-18</sub>)aryl, or (C<sub>6-18</sub>)aryl substituted by aminocarbonyl, halogen or halo(C<sub>1-6</sub>)alkyl, or  
a compound of formula



wherein R<sub>1</sub> is as defined in claim 2.